Dave Sprengers

Dave Sprengers is a researcher at Erasmus MC, affiliated with the Department of Gastroenterology & Hepatology within the Erasmus School of Medicine. His work is centered on liver diseases, particularly hepatocellular carcinoma (HCC), cholangiocarcinoma, and liver transplantation, with a strong focus on clinical and translational research.

His research interests span hepatocellular carcinoma, liver transplantation, immune checkpoint biology, T cell immunology, and molecular oncology. He actively investigates epigenetic markers such as DNA methylation for early cancer detection and explores advanced therapies like holmium-166 radioembolization, including dosimetry and functional imaging.

The recent trend in his publications highlights a multidisciplinary approach combining clinical hepatology, nuclear medicine, and molecular diagnostics, with a consistent emphasis on improving outcomes in liver cancer patients. His work often involves collaborative, team-based research across specialties.

Scientific awards:

• No awards listed in the provided text.

Dave Sprengers has supervised research work, as indicated by three supervised items in the database, suggesting involvement in mentoring junior researchers or students. While specific grants are not mentioned, his extensive publication record in high-impact journals implies involvement in funded research projects. He collaborates widely within Erasmus MC and with external institutions, particularly in nuclear medicine and oncology.

He is part of a research network focused on liver cancer, immune regulation, and interventional therapies, contributing to both clinical studies and molecular investigations. His team likely includes clinicians, radiologists, molecular biologists, and data analysts working on liver disease mechanisms and treatments.